Fierce Medtech Names CVRx as One of its “Fierce 15” Companies
15. März 2021 10:00 ET
|
CVRx, Inc.
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announces it has been selected...
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
05. Januar 2021 10:55 ET
|
CVRx, Inc.
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
03. Dezember 2020 11:54 ET
|
CVRx, Inc.
MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
18. November 2020 14:56 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...